{Reference Type}: Case Reports
{Title}: Use of everolimus following kidney transplantation during pregnancy: A case report and systematic review.
{Author}: Chai PY;Lin C;Kao CC;Lin LM;Chen YH;Sun CY;
{Journal}: Taiwan J Obstet Gynecol
{Volume}: 62
{Issue}: 5
{Year}: 2023 Sep
{Factor}: 1.944
{DOI}: 10.1016/j.tjog.2023.07.026
{Abstract}: <B>OBJECTIVE: </B>There is limited safety data on the use of everolimus during pregnancy. In this study, we present the maternal and neonatal outcomes of everolimus used throughout the course of pregnancy and conducted a systematic review of reports of everolimus use after organ transplantation during pregnancy.<BR><B>METHODS: </B>A woman with type 1 diabetes who underwent kidney transplantation was treated with tacrolimus, everolimus, and prednisolone. Two years later, she became pregnant. At 27 weeks of gestation, an emergent cesarean delivery was performed owing to severe preeclampsia and fetal distress. No congenital malformation was noted in the baby at a corrected age of 4 months, and the maternal renal function remained stable.<BR><B>CONCLUSIONS: </B>Our systematic review did not identify evidence of teratogenicity in babies exposed to everolimus as an immunosuppressant after transplantation. To better assess the risk of exposure to everolimus during pregnancy, all cases of new pregnancies occurring in transplant recipients receiving treatment with mammalian target of rapamycin inhibitor inhibitors should be reported.